Abstract
Placenta Accreta Spectrum (PAS) disorders include a complex range of placental pathologies associated with significant maternal morbidity and mortality. Diagnosis of PAS relies on ultrasonographic findings, limited by a positive predictive value of 61-73%. Since placental neovascularization is a notable finding in >90% of PAS, our objective was to determine if urinary vascular endothelial growth factor (VEGF) is associated with PAS pathology and post-operative morbidity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
